Fuller & Thaler Asset Management Inc. Sells 18,074 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Fuller & Thaler Asset Management Inc. trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,351,880 shares of the specialty pharmaceutical company's stock after selling 18,074 shares during the period. Fuller & Thaler Asset Management Inc. owned approximately 4.19% of Collegium Pharmaceutical worth $38,731,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its holdings in shares of Collegium Pharmaceutical by 6.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,138 shares of the specialty pharmaceutical company's stock worth $950,000 after acquiring an additional 1,977 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Collegium Pharmaceutical by 148.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,711 shares of the specialty pharmaceutical company's stock valued at $336,000 after purchasing an additional 7,000 shares during the last quarter. MetLife Investment Management LLC boosted its position in shares of Collegium Pharmaceutical by 8.5% in the fourth quarter. MetLife Investment Management LLC now owns 19,987 shares of the specialty pharmaceutical company's stock valued at $573,000 after acquiring an additional 1,558 shares during the period. XTX Topco Ltd purchased a new position in Collegium Pharmaceutical during the fourth quarter worth about $236,000. Finally, Barclays PLC increased its holdings in shares of Collegium Pharmaceutical by 6.3% in the 4th quarter. Barclays PLC now owns 79,754 shares of the specialty pharmaceutical company's stock worth $2,286,000 after buying an additional 4,702 shares during the last quarter.

Analyst Ratings Changes

Several analysts have weighed in on COLL shares. Needham & Company LLC reiterated a "buy" rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Piper Sandler cut their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 4th. StockNews.com lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. Finally, HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $43.60.

Collegium Pharmaceutical Price Performance

NASDAQ COLL traded down $0.33 during trading on Wednesday, hitting $27.27. 36,059 shares of the stock traded hands, compared to its average volume of 441,499. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $42.29. The firm has a 50-day simple moving average of $28.30 and a 200-day simple moving average of $30.60. The company has a market capitalization of $876.24 million, a P/E ratio of 11.75 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insider Activity

In related news, EVP Scott Dreyer sold 2,255 shares of the stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the sale, the executive vice president now directly owns 124,421 shares of the company's stock, valued at $3,732,630. This represents a 1.78 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Colleen Tupper sold 10,445 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares of the company's stock, valued at $4,959,032.46. This trade represents a 5.95 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 81,693 shares of company stock valued at $2,334,994. 2.51% of the stock is currently owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.